Unraveling the protein glycosylation of Plasmodium falciparum is crucial for development of novel therapeutics against malaria

Projektinformationen

SugarBlock

ID Finanzhilfevereinbarung: 703305

DOI 10.3030/703305

Abgeschlossenes Projekt

EK-Unterschriftsdatum 21 März 2016

Startdatum 29 August 2016

Enddatum 28 August 2018

Finanziert unter

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Gesamtkosten € 158 121,60

EU-Beitrag € 158 121,60

Koordiniert durch

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA
Spain

Ziel

Annually, malaria causes 200 million clinical cases and more than half a million deaths. Works carried out more than 40 years ago demonstrated that a malaria vaccine offering sterile protective immunity in humans was possible, but the efforts to develop a modern, recombinant ‘subunit’ malaria vaccine only confer short term protection against clinical malaria in 35-50% of recipients. Several evidences support the presence of foreign short N-glycans and other minor glycosylations in the surfaces of the parasite, Plasmodium faciparum, the causative agent of malaria. In addition, recent studies show that Plasmodium sporozoites present also unknown α-galactose containing antigens in their surface and that antibodies against them provide sterile protection against malaria in mice. We propose to completely characterize the protein glycosylation present in the surface of the extracellular sporozoites, that travel from the mosquito to the liver, and merozoites, that invade human erythrocytes. We will use different quasi-targeted glycoproteomic approaches, based on the expected simplicity and low variability of these glycosylations in the parasite surface and their affinity to well characterized lectins. The investigation of these uncommon parasitic glycosylations may expose an unexpected Achilles’ heel in the Plasmodium parasite that could be exploited to halt sporozoite development and/or stop merozoite invasion and induce protection against malaria, mimicking what has already been achieved using carbohydrate-protein conjugate vaccines against bacterial infections.

Wissenschaftliches Gebiet

• medical and health sciences › health sciences › infectious diseases › malaria
• medical and health sciences › health sciences › public health
• medical and health sciences › basic medicine › immunology › immunisation
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines
• natural sciences › biological sciences › zoology › invertebrate zoology

Programm/Programme

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Thema/Themen

• MSCA-IF-2015-EF - Marie Skłodowska-Curie Individual Fellowships (IF-EF)

Aufforderung zur Vorschlagseinreichung

H2020-MSCA-IF-2015

Finanzierungsplan

MSCA-IF-EF-ST - Standard EF

Koordinator

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA

• Netto-EU-Beitrag: € 158 121,60
• Adresse: C ROSSELLO 132 PLANTA 05 ; 08036 Barcelona ; Spanien
• Region: Este › Cataluña › Barcelona
• Aktivitätstyp: Research Organisations
• Gesamtkosten: € 158 121,60